Takahiro Ryu

Publications (2)0 Total impact

• Article: Current management of esophageal squamous-cell carcinoma in Japan and other countries.

  Katsuhiko Higuchi, Wasaburo Koizumi, Satoshi Tanabe, Tohru Sasaki, Chikatoshi Katada, Mizutomo Azuma, Kento Nakatani, Kenji Ishido, Akira Naruke, Takahiro Ryu
  [show abstract] [hide abstract]
  ABSTRACT: The incidence of adenocarcinoma of the distal esophagus or esophagogastric junction has increased considerably in Western countries during the past 3 decades, whereas the incidence of squamous-cell carcinoma has decreased slightly. In Japan, most esophageal cancers are squamous-cell carcinomas. Endoscopic examinations are more frequently performed in Japan for routine screening and diagnosis and treatment than in other countries, thereby increasing the detection rate of superficial esophageal carcinomas. In Europe and North America, many clinical trials have been conducted to assess the effectiveness of neoadjuvant chemoradiotherapy followed by surgery in patients with resectable, advanced esophageal cancer. In Japan, surgical resection had been the mainstay of treatment for esophageal cancer. Since the results of the Japan Clinical Oncology Group (JCOG) 9907 study were reported, neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil followed by surgery has emerged as a new standard treatment. As for definitive chemoradiotherapy, cisplatin, 5-fluorouracil, and concurrent radiotherapy dosed to 50.4 Gy are used as standard treatment in a randomized clinical trial performed in North America. In patients who have T4 tumors and/or M1 lymph-node metastasis, chemoradiotherapy with cisplatin and 5-fluorouracil is considered standard treatment, but docetaxel, cisplatin, and 5-fluorouracil plus concurrent radiotherapy is also being studied. Controlled studies have not shown that palliative chemotherapy is superior to best supportive care, but cisplatin plus 5-fluorouracil is still considered standard therapy. Clinical trials of targeted agents are in progress. It is hoped that targeted agents will be effective for esophageal cancer.
  Gastrointestinal cancer research: GCR 08/2009; 3(4):153-61.
• Article: [Clinical development of S-1 (TS-1) for advanced gastric cancer].

  Koizumi Wasaburo, Satoshi Tanabe, Katsuhiko Higuchi, Toru Sasaki, Norisuke Nakayama, Shizuka Mihara, Kento Nakatani, Ken Nishimura, Takuya Shimoda, Mizutomo Azuma, Chikatoshi Katada, Noboru Hanaoka, Akira Naruke, Takahiro Ryu, Kenji Ishido, Katsunori Saigenji
  [show abstract] [hide abstract]
  ABSTRACT: The 5-FU plus cisplatin containing regimen like FP, ECF and DCF, is considered to be the most effective treatment for advanced gastric cancer in the United States, Europe, and Korea. In Japan, oral fluoropyrimidine S-1 (TS-1) is currently considered to be the first candidate as the standard drug for advanced gastric cancer. S-1 based combination therapies with other promising drugs like cisplatin, irinotecan and taxanes, are expected to yield good results. Above all, S-1+CDDP therapy showed a high efficacy and expected to be a standard therapy for advanced gastric cancer. Two large phase III studies, JCOG 9912 5-FU vs S-1 vs CPT-11 +CDDP and S-1 vs S-1+CDDP, are now on going to establish an acceptable frontline standard for patients with AGC. We therefore need to develop new agents and combination chemotherapy regimens to achieve a greater survival benefit in AGC.
  Gan to kagaku ryoho. Cancer & chemotherapy 07/2006; 33 Suppl 1:57-63.